USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Centro DE Ingeniería Genética Y Biotecnología

USPTO PatentsView assignee record - 39 granted patents across 22 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

9.8

Avg claims per patent

-59%

5-year grant velocity

The verdict

According to USPTO PatentsView, Centro ranks #8,179 of 50,000 tracked US assignees by granted-patent volume, with 39 patents across 22 technology areas.

#8,179
of 50,000 US assignees by volume: Top 34%
by Innovation Score (40.9/100): 9.8
avg claims per patent: -59%
grant velocity, last 5 yrs

Portfolio overview

Centro DE Ingeniería Genética Y Biotecnología has been granted 39 US utility patents between 2015 and 2025, placing Centro DE Ingeniería Genética Y Biotecnología at #8,179 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Centro DE Ingeniería Genética Y Biotecnología is one of the more focused assignees in the PatentsView dataset. By volume, Centro sits between Bedford Systems Llc (39 patents, rank #8,170) and Catalina Marketing Corporation (39 patents, rank #8,178) - the closest US assignees by grant volume. The composite Innovation Score of 40.9/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 11 grants, compared with 27 in the 2015–2019 window, a -59% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Centro DE Ingeniería Genética Y Biotecnología's 9.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 22 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Bedford Systems

39
Biomed Valley Dis…

39
Brose Fahrzeugtei…

39
CACI —Federal

39
Cynosure

39
Can't Live Withou…

39
Capbran Holdings

39
Catalina Marketing

39
Centro DE Ingenie… ◀

39

What this shows Centro holds 39 patents at rank #8,174, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Centro

By rank, the assignees closest to #8,174 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Centro's primary technology class.

Centro's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Centro DE Ingeniería Genética Y Biotecnología patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	25.6%
2016	7	17.9%
2017	5	12.8%
2018	3	7.7%
2019	2	5.1%
2020	1	2.6%
2021	4	10.3%
2022	2	5.1%
2023	2	5.1%
2024	2	5.1%
2025partial year	1	2.6%

Which technologies does Centro DE Ingeniería Genética Y Biotecnología patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 31

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 31

C07K - PEPTIDES 19

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 13

A23K - FODDER 5

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 4

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 2

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 2

A61Q - SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS 2

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 2

C12Y - ENZYMES 2

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 2

A23L - FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF 2

C07D - HETEROCYCLIC COMPOUNDS 2

A01H - NEW PLANTS OR ; NON-TRANSGENIC; PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES 1

Top 15 of 22 technology areas

Grant record at a glance

Portfolio Volume 39 grants

CPC subclasses 22

Avg. claims / grant 9.8

Velocity -59%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#8,179

of 50,000 tracked assignees

Innovation Score

40.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Centro DE Ingeniería Genética Y Biotecnología rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Centro DE Ingeniería Genética Y Biotecnología ranks #8,179 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Centro DE Ingeniería Genética Y Biotecnología hold?

Centro DE Ingeniería Genética Y Biotecnología holds 39 US utility patents granted between 2015 and 2025, spanning 22 technology areas.

What is Centro DE Ingeniería Genética Y Biotecnología's Innovation Score?

Centro DE Ingeniería Genética Y Biotecnología has an Innovation Score of 40.9 out of 100 (top 34% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Centro DE Ingeniería Genética Y Biotecnología focus on?

Centro DE Ingeniería Genética Y Biotecnología's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 31 patents. Grants appear in 22 CPC subclasses total.

Is Centro DE Ingeniería Genética Y Biotecnología's patent grant rate increasing or decreasing?

Centro DE Ingeniería Genética Y Biotecnología's recent grant velocity is -59% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Centro DE Ingeniería Genética Y Biotecnología's patents?

Centro DE Ingeniería Genética Y Biotecnología's patents average 9.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Centro DE Ingeniería Genética Y Biotecnología patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Centro's 39 grants land it in the top 34% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Centro ranks #8,179 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Cite this page

Plainpatent, “Centro DE Ingeniería Genética Y Biotecnología Patent Portfolio.” Compiled from the underlying federal/official data source; data as of 2015–2025. https://plainpatent.com/company/centro-de-ingenier%C3%ADa-gen%C3%A9tica-y-biotecnolog%C3%ADa/

Formal citation formats (APA / MLA)

APA: Plainpatent. (2015). Centro DE Ingeniería Genética Y Biotecnología Patent Portfolio. Retrieved August 13, 2026, from https://plainpatent.com/company/centro-de-ingenier%C3%ADa-gen%C3%A9tica-y-biotecnolog%C3%ADa/

MLA: "Centro DE Ingeniería Genética Y Biotecnología Patent Portfolio." Plainpatent, 2015, https://plainpatent.com/company/centro-de-ingenier%C3%ADa-gen%C3%A9tica-y-biotecnolog%C3%ADa/.

You are welcome to quote these figures with attribution to Plainpatent and the underlying source. The URL above is stable. Licensed CC BY 4.0 - reuse with attribution.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.